Adage Capital Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Adage Capital Partners’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-438,437	Closed	-$5.89M	–	964
2023 Q1	$5.89M	Buy	+438,437	New	+$7.59M	0.01%	687
2022 Q4	–	Sell	-50,000	Closed	-$698K	–	1069
2022 Q3	$698K	Buy	+50,000	New	+$805K	﹤0.01%	905
2022 Q2	–	Sell	-100,000	Closed	-$1.63M	–	1163
2022 Q1	$1.63M	Sell	100,000 -1,133,000	-92%	-$17.7M	﹤0.01%	912
2021 Q4	$20.1M	Buy	+1,233,000	New	+$20.8M	0.04%	460
2020 Q3	–	Sell	-550,000	Closed	-$26.4M	–	827
2020 Q2	$26.4M	Buy	+550,000	New	+$42.5M	0.07%	317
2019 Q3	–	Sell	-333,100	Closed	-$26.5M	–	769
2019 Q2	$26.5M	Sell	333,100 -171,900	-34%	-$15.4M	0.07%	312
2019 Q1	$56.5M	Buy	505,000 +367,000	+266%	+$40.1M	0.14%	180
2018 Q4	$13.9M	Buy	+138,000	New	+$14.3M	0.04%	426
2015 Q4	–	Sell	-77,000	Closed	-$12.8M	–	751
2015 Q3	$12.8M	Sell	77,000 -10,000	-11%	-$2.2M	0.04%	482
2015 Q2	$21M	Sell	87,000 -24,975	-22%	-$6.65M	0.05%	402
2015 Q1	$31.6M	Sell	111,975 -8,025	-7%	-$1.74M	0.08%	323
2014 Q4	$18.7M	Buy	120,000 +79,000	+193%	+$14.6M	0.05%	420
2014 Q3	$9.7M	Buy	41,000 +26,000	+173%	+$6.63M	0.02%	541
2014 Q2	$3.55M	Sell	15,000 -40,264	-73%	-$10.6M	0.01%	629
2014 Q1	$18.2M	Sell	55,264 -119,736	-68%	-$40.4M	0.05%	402
2013 Q4	$11.9M	Sell	175,000 -235,655	-57%	-$13.6M	0.03%	494
2013 Q3	$28.3M	Sell	410,655 -27,779	-6%	-$1.37M	0.08%	291
2013 Q2	$19.7M	Buy	+438,434	New	+$15M	0.06%	363

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Adage Capital Partners's ICPT Position: Q2 2023 in Review

Adage Capital Partners sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2023, closing a stake of 438,437 shares — an estimated $5.89M sold.

Adage Capital Partners first reported a position in ICPT in Q2 2013 and held it in 18 quarters. The position peaked at $56.5M in Q1 2019. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

Adage Capital Partners reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Adage Capital Partners sold 438,437 Intercept Pharmaceuticals, Inc. shares in Q2 2023, an estimated $5.89M.
Adage Capital Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 18 quarters.
Adage Capital Partners's Intercept Pharmaceuticals, Inc. position peaked at $56.5M in Q1 2019.
126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Adage Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.